Phathom Pharmaceuticals (NASDAQ:PHAT – Get Rating) had its target price lowered by equities researchers at The Goldman Sachs Group from $32.00 to $15.00 in a research note issued to investors on Tuesday, Stock Target Advisor reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective would suggest a […]
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Rating) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 10,110 call options on the company. This is an increase of approximately 23,971% compared to the typical daily volume of 42 call options. Shares of PHAT stock traded down $0.74 during trading on Wednesday, reaching […]